Yoshitaka Miyakawa
Research Subjects
Yoshitaka Miyakawa has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
Yasuo Ikeda
Waseda University
8 shared publicationsHideo Uchida
Department of Internal Medicine, Tokyo Electric Power Company Hospital, Shinjuku-ku, Tokyo, Japan
4 shared publicationsMitsuru Murata
Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan
3 shared publicationsShinichiro Okamoto
Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
3 shared publicationsYoshiaki Tomiyama
Osaka University Hospital
3 shared publicationsKatsutoshi Ozaki
Jichi Medical University
2 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by Elsevier in SSRN Electronic Journal
Long-Term Safety and Efficacy of Efgartigimod in Adults with Primary Immune Thrombocytopenia: Interim Results of the ADVANCE IV+ Phase 3 Trial
Background: ADVANCE IV+ (NCT04225156) is an ongoing, phase 3, open-label extension of the ADVANCE IV trial to assess long-term safety and efficacy of efgartigimod in adults (≥18 years) with chronic or persistent immune thrombocytopenia (ITP; platelet count <30 × 109/L).Methods: In ADVANCE IV, participants were randomised 2:1 to receive intravenous (IV) efgartigimod (10 mg/kg) or placebo once weekly (QW) for weeks 1–4, then QW or every other week (Q2W), based on platelet counts, up to week 24. Participants completing ADVANCE IV and meeting inclusion criteria could roll over to ADVANCE IV+. All participants received efgartigimod IV (10 mg/kg) QW or Q2W, dependent upon platelet counts. The primary objective was safety (frequency/severity of treatment-emergent adverse events [TEAEs]; vital signs; laboratory assessments); secondary objectives included assessment of long-term efficacy.Findings: In this interim analysis (data cutoff: 1 September 2023), 101 individuals (mean [standard deviation] age: 49∙7 [17∙2] years) rolled over from ADVANCE IV: 63 from the efgartigimod treatment group (EFG–EFG) and 38 from the placebo group (PBO–EFG). Most (96/101 [95∙0%]) were white and 51∙5% (52/101) were male. The majority of participants (93/101 [92∙1%]) reported one or more TEAE, with most mild or moderate in severity. Serious adverse events (AEs) were reported by 16/101 participants (15∙8%) (EFG–EFG: 10/63 [15∙9%]; PBO–EFG: 6/38 [15∙8%]). Severe (grade ≥3) AEs were reported by 19 participants (18∙8%) (EFG–EFG: 11/63 [17∙5%]; PBO–EFG: 8/38 [21∙1]). There were no treatment-related deaths. A sustained platelet count response (≥50 × 109/L for ≥4/6 weeks between weeks 19 and 24) was observed in 33/101 participants (32∙7%) (EFG–EFG: 23/63 [36∙5%]; PBO–EFG: 10/38 [26∙3%]). The proportion of sustained platelet count responders remained stable throughout the trial.Interpretation: ADVANCE IV+ demonstrated long-term safety and efficacy of efgartigimod in individuals with chronic or persistent ITP, highlighting its value as a treatment option in this patient group.
- 24 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLong-Term Safety and Efficacy of Efgartigimod in Adults with Primary Immune Thrombocytopenia: Interim Results of the ADVANCE IV+ Phase 3 Trial
Background: ADVANCE IV+ (NCT04225156) is an ongoing, phase 3, open-label extension of the ADVANCE IV trial to assess long-term safety and efficacy of efgartigimod in adults (≥18 years) with chronic or persistent immune thrombocytopenia (ITP; platelet count <30 × 109/L).Methods: In ADVANCE IV, participants were randomised 2:1 to receive intravenous (IV) efgartigimod (10 mg/kg) or placebo once weekly (QW) for weeks 1–4, then QW or every other week (Q2W), based on platelet counts, up to week 24. Participants completing ADVANCE IV and meeting inclusion criteria could roll over to ADVANCE IV+. All participants received efgartigimod IV (10 mg/kg) QW or Q2W, dependent upon platelet counts. The primary objective was safety (frequency/severity of treatment-emergent adverse events [TEAEs]; vital signs; laboratory assessments); secondary objectives included assessment of long-term efficacy.Findings: In this interim analysis (data cutoff: 1 September 2023), 101 individuals (mean [standard deviation] age: 49∙7 [17∙2] years) rolled over from ADVANCE IV: 63 from the efgartigimod treatment group (EFG–EFG) and 38 from the placebo group (PBO–EFG). Most (96/101 [95∙0%]) were white and 51∙5% (52/101) were male. The majority of participants (93/101 [92∙1%]) reported one or more TEAE, with most mild or moderate in severity. Serious adverse events (AEs) were reported by 16/101 participants (15∙8%) (EFG–EFG: 10/63 [15∙9%]; PBO–EFG: 6/38 [15∙8%]). Severe (grade ≥3) AEs were reported by 19 participants (18∙8%) (EFG–EFG: 11/63 [17∙5%]; PBO–EFG: 8/38 [21∙1]). There were no treatment-related deaths. A sustained platelet count response (≥50 × 109/L for ≥4/6 weeks between weeks 19 and 24) was observed in 33/101 participants (32∙7%) (EFG–EFG: 23/63 [36∙5%]; PBO–EFG: 10/38 [26∙3%]). The proportion of sustained platelet count responders remained stable throughout the trial.Interpretation: ADVANCE IV+ demonstrated long-term safety and efficacy of efgartigimod in individuals with chronic or persistent ITP, highlighting its value as a treatment option in this patient group.
- Open Access
- 24 March 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 2 (2)
Japanese database analysis: effectiveness of early initiation of TPO-RA treatment in tapering corticosteroid dose in ITP
- 24 March 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 2 (2)
Open AccessJapanese database analysis: effectiveness of early initiation of TPO-RA treatment in tapering corticosteroid dose in ITP
- Open Access
- 14 October 2024
- Published by Springer Nature in International Journal of Hematology
- Vol. 120 (6) , 656-664
Long-term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease
Sutimlimab, a complement inhibitor, has recently been approved in Japan for treating cold agglutinin disease (CAD). We report the safety and efficacy of sutimlimab in Japanese patients with CAD who completed a global phase 3 clinical trial (CARDINAL/CADENZA: 26-week treatment with 1–2 years of open-label extension [OLE] periods) and subsequently participated in the Japanese OLE study. Patients with a recent history of blood transfusion (CARDINAL, n = 3) and those without (CADENZA, n = 4) were analyzed (71.4% female; median [range] baseline age: 70 [46–83] years). For CARDINAL/CADENZA, the treatment duration (median [range]) was 140.9 (104.9–157.3) weeks, and the cessation period was 70 (61–133) weeks. For the Japanese OLE study, the treatment duration was 47.1 (15.1–49.1) weeks. Three (42.9%) patients experienced treatment-related and treatment-emergent adverse events (TEAEs): injection site erythema, cystitis bacterial, viral infection, and blood pressure increased during CARDINAL/CADENZA. One (14.3%) patient experienced one treatment-related TEAE (urinary tract infection) during the Japanese OLE study. One patient died of renal failure, considered unrelated to sutimlimab, that was exacerbated by hepatorenal syndrome due to liver cirrhosis and bacterial peritonitis, in addition to CKD. Hemoglobin and bilirubin levels improved during treatment but deteriorated after withdrawal and recovered on retreatment. Sutimlimab was well tolerated over a median of 3.8 years, with no new safety concerns identified during retreatment.
- 14 October 2024
- Published by Springer Nature in International Journal of Hematology
- Vol. 120 (6) , 656-664
Open AccessLong-term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease
Sutimlimab, a complement inhibitor, has recently been approved in Japan for treating cold agglutinin disease (CAD). We report the safety and efficacy of sutimlimab in Japanese patients with CAD who completed a global phase 3 clinical trial (CARDINAL/CADENZA: 26-week treatment with 1–2 years of open-label extension [OLE] periods) and subsequently participated in the Japanese OLE study. Patients with a recent history of blood transfusion (CARDINAL, n = 3) and those without (CADENZA, n = 4) were analyzed (71.4% female; median [range] baseline age: 70 [46–83] years). For CARDINAL/CADENZA, the treatment duration (median [range]) was 140.9 (104.9–157.3) weeks, and the cessation period was 70 (61–133) weeks. For the Japanese OLE study, the treatment duration was 47.1 (15.1–49.1) weeks. Three (42.9%) patients experienced treatment-related and treatment-emergent adverse events (TEAEs): injection site erythema, cystitis bacterial, viral infection, and blood pressure increased during CARDINAL/CADENZA. One (14.3%) patient experienced one treatment-related TEAE (urinary tract infection) during the Japanese OLE study. One patient died of renal failure, considered unrelated to sutimlimab, that was exacerbated by hepatorenal syndrome due to liver cirrhosis and bacterial peritonitis, in addition to CKD. Hemoglobin and bilirubin levels improved during treatment but deteriorated after withdrawal and recovered on retreatment. Sutimlimab was well tolerated over a median of 3.8 years, with no new safety concerns identified during retreatment.
- Open Access
- 1 January 2024
- Published by Japanese Society on Thrombosis and Hemostasis in Japanese Journal of Thrombosis and Hemostasis
- Vol. 35 (4) , 455-460
Neonatal Fc receptor antagonist, efgartigimod, for chronic ITP
胎児性Fc受容体阻害薬エフガルチギモドは,2024年3月に世界で初めて慢性ITPの適応症を日本で取得した.エフガルチギモドは自己抗体を含む総IgG濃度を約6割減少させることで,治療開始から1週間後に血小板数を速やかに増やす.前治療が無効な難治例に対するプラセボ対照,二重盲検化,国際共同Phase 3試験で,エフガルチギモドの血小板を安定に増加させる有効性と安全性が確認された.本稿では胎児性Fc受容体研究の歴史,エフガルチギモドの薬理機序と開発動向,慢性ITPに対するエフガルチギモドのPhase 3試験と臨床的位置づけなどを紹介する.
- 1 January 2024
- Published by Japanese Society on Thrombosis and Hemostasis in Japanese Journal of Thrombosis and Hemostasis
- Vol. 35 (4) , 455-460
Open AccessNeonatal Fc receptor antagonist, efgartigimod, for chronic ITP
胎児性Fc受容体阻害薬エフガルチギモドは,2024年3月に世界で初めて慢性ITPの適応症を日本で取得した.エフガルチギモドは自己抗体を含む総IgG濃度を約6割減少させることで,治療開始から1週間後に血小板数を速やかに増やす.前治療が無効な難治例に対するプラセボ対照,二重盲検化,国際共同Phase 3試験で,エフガルチギモドの血小板を安定に増加させる有効性と安全性が確認された.本稿では胎児性Fc受容体研究の歴史,エフガルチギモドの薬理機序と開発動向,慢性ITPに対するエフガルチギモドのPhase 3試験と臨床的位置づけなどを紹介する.
- Open Access
- 1 January 2022
- Published by Japanese Society on Thrombosis and Hemostasis in Japanese Journal of Thrombosis and Hemostasis
- Vol. 33 (5) , 576-579
COVID-19 vaccination and immune thrombocytopenia
- 1 January 2022
- Published by Japanese Society on Thrombosis and Hemostasis in Japanese Journal of Thrombosis and Hemostasis
- Vol. 33 (5) , 576-579
Open AccessCOVID-19 vaccination and immune thrombocytopenia
- 25 October 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (2) , 304-307
Pure red cell aplasia accompanied by COVID-19 successfully treated using cyclosporine
- 25 October 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (2) , 304-307
Pure red cell aplasia accompanied by COVID-19 successfully treated using cyclosporine
- Open Access
- 1 January 2017
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 56 (9) , 1085-1088
Long-term Eculizumab Treatment Contributes to Recovery from End-stage Renal Disease Caused by Atypical Hemolytic Uremic Syndrome
We experienced a favorable outcome in an adult case of atypical hemolytic uremic syndrome (aHUS) after long-term eculizumab treatment. A 38-year-old Japanese man with a history of central retinal vein occlusion was admitted to our hospital with progressive dyspnea. He was found to have non-immune hemolytic anemia, thrombocytopenia, and acute renal failure two weeks after an episode of the common cold. Plasma exchange was ineffective; therefore, we initiated eculizumab after we excluded other thrombotic microangiopathies. Although long-term peritoneal dialysis was required, we successfully discontinued dialysis 18 months after the onset of aHUS with eculizumab.
- 1 January 2017
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 56 (9) , 1085-1088
Open AccessLong-term Eculizumab Treatment Contributes to Recovery from End-stage Renal Disease Caused by Atypical Hemolytic Uremic Syndrome
We experienced a favorable outcome in an adult case of atypical hemolytic uremic syndrome (aHUS) after long-term eculizumab treatment. A 38-year-old Japanese man with a history of central retinal vein occlusion was admitted to our hospital with progressive dyspnea. He was found to have non-immune hemolytic anemia, thrombocytopenia, and acute renal failure two weeks after an episode of the common cold. Plasma exchange was ineffective; therefore, we initiated eculizumab after we excluded other thrombotic microangiopathies. Although long-term peritoneal dialysis was required, we successfully discontinued dialysis 18 months after the onset of aHUS with eculizumab.
- 17 May 2016
- Published by Springer Nature in International Journal of Hematology
- Vol. 104 (2) , 228-235
Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy
Thrombotic thrombocytopenic purpura (TTP), while rare, is a potentially life-threatening disorder. Plasma exchange (PE) is considered the primary treatment for TTP. In Western countries, rituximab, an anti-CD20 antibody, is recommended with PE for the treatment of refractory/relapsed TTP, and as up-front therapy in newly diagnosed TTP with neurological/cardiac pathology. The present open-label, single-arm, multicenter study evaluated the efficacy and safety of rituximab in Japanese patients with refractory/relapsed TTP. Patients received rituximab 375 mg/m2 intravenously, once weekly for a total of four treatments, with PE and steroids. Of six evaluable patients in the full analysis set, two met the primary efficacy endpoint (platelet count >150 × 109/L at week 4), yielding a 33.3 % response rate (95 % confidence interval: 4.3–77.7). While the lower confidence limit of the primary efficacy endpoint failed to reach the pre-specified threshold of 30 %, clinically significant recovery of platelet count with discontinuation of PE, increase of ADAMTS13 activity, disappearance of ADAMTS13 inhibitor, and improvement of TTP-associated clinical manifestations were observed after rituximab therapy in all patients. No safety concerns were identified in this study; therefore, rituximab is considered a useful treatment option in Japanese TTP patients who are refractory to conventional therapy. Trial registration JMA-IIA00160.
- 17 May 2016
- Published by Springer Nature in International Journal of Hematology
- Vol. 104 (2) , 228-235
Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy
Thrombotic thrombocytopenic purpura (TTP), while rare, is a potentially life-threatening disorder. Plasma exchange (PE) is considered the primary treatment for TTP. In Western countries, rituximab, an anti-CD20 antibody, is recommended with PE for the treatment of refractory/relapsed TTP, and as up-front therapy in newly diagnosed TTP with neurological/cardiac pathology. The present open-label, single-arm, multicenter study evaluated the efficacy and safety of rituximab in Japanese patients with refractory/relapsed TTP. Patients received rituximab 375 mg/m2 intravenously, once weekly for a total of four treatments, with PE and steroids. Of six evaluable patients in the full analysis set, two met the primary efficacy endpoint (platelet count >150 × 109/L at week 4), yielding a 33.3 % response rate (95 % confidence interval: 4.3–77.7). While the lower confidence limit of the primary efficacy endpoint failed to reach the pre-specified threshold of 30 %, clinically significant recovery of platelet count with discontinuation of PE, increase of ADAMTS13 activity, disappearance of ADAMTS13 inhibitor, and improvement of TTP-associated clinical manifestations were observed after rituximab therapy in all patients. No safety concerns were identified in this study; therefore, rituximab is considered a useful treatment option in Japanese TTP patients who are refractory to conventional therapy. Trial registration JMA-IIA00160.
- 14 October 2015
- Published by Springer Nature in International Journal of Hematology
- Vol. 102 (6) , 654-661
Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy
Primary immune thrombocytopenia (ITP) is an autoimmune disease mediated by the production of auto-antibody against platelets. Rituximab, an anti-CD20 antibody, is reported to be useful for treatment of ITP. In Japan, however, robust evidence on this treatment has not been accumulated. Hence, we conducted this open-label phase III clinical trial to confirm the efficacy and safety of rituximab, administered at 375 mg/m2 once per week at weekly intervals for 4 consecutive weeks in Japanese patients with chronic ITP, who had relapsed and were refractory to conventional therapy. The primary endpoint was defined as the percentage of patients with a platelet count above 50 × 109/L at week 24 after the first dose of rituximab, which was 30.8 % of 26 patients (95 % confidence interval 14.3–51.8 %). Although the lower confidence limit of primary endpoint failed to meet the pre-specified threshold of 20 %, the clinical efficacy of rituximab is substantial in consideration of the 2 % response rate in the placebo arm in other clinical studies in patients with chronic ITP. We conclude that rituximab is clinically useful and safe in the treatment of Japanese patients with chronic ITP, achieving the goal of maintaining platelet count and reducing risk of bleeding while minimizing treatment-related toxicity.
- 14 October 2015
- Published by Springer Nature in International Journal of Hematology
- Vol. 102 (6) , 654-661
Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy
Primary immune thrombocytopenia (ITP) is an autoimmune disease mediated by the production of auto-antibody against platelets. Rituximab, an anti-CD20 antibody, is reported to be useful for treatment of ITP. In Japan, however, robust evidence on this treatment has not been accumulated. Hence, we conducted this open-label phase III clinical trial to confirm the efficacy and safety of rituximab, administered at 375 mg/m2 once per week at weekly intervals for 4 consecutive weeks in Japanese patients with chronic ITP, who had relapsed and were refractory to conventional therapy. The primary endpoint was defined as the percentage of patients with a platelet count above 50 × 109/L at week 24 after the first dose of rituximab, which was 30.8 % of 26 patients (95 % confidence interval 14.3–51.8 %). Although the lower confidence limit of primary endpoint failed to meet the pre-specified threshold of 20 %, the clinical efficacy of rituximab is substantial in consideration of the 2 % response rate in the placebo arm in other clinical studies in patients with chronic ITP. We conclude that rituximab is clinically useful and safe in the treatment of Japanese patients with chronic ITP, achieving the goal of maintaining platelet count and reducing risk of bleeding while minimizing treatment-related toxicity.
- Open Access
- 22 January 2015
- Published by Springer Nature in BMC Health Services Research
- Vol. 15 (1) , 2
Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease in which the platelet count falls to <100 × 109/L. Corticosteroids are recommended as the first-line treatment, splenectomy is recommended as the second-line treatment, and thrombopoietin receptor agonists (TPO-RAs) and rituximab are recommended as the third-line treatments for ITP in Japanese ITP treatment guidelines. However, in Japan, rituximab is not eligible for reimbursement for the treatment of ITP. The cost-effectiveness of ITP treatment has not been investigated in Japan. Therefore, in this study, the cost-effectiveness of adding rituximab treatment to the existing treatments indicated for ITP in Japan, namely splenectomy and the TPO-RA romiplostim, was investigated based on the scenario that rituximab is eligible for reimbursement in Japan as a treatment for ITP. The efficacy endpoint was set as the number of years with a platelet count ≥30 × 109/L. The analysis was conducted from the healthcare payer’s perspective. If the first treatment is ineffective or relapse occurs, then the patient is given the following treatment. The analyzed treatment order consisted of three patterns: splenectomy-romiplostim (sequence 1), splenectomy-romiplostim-rituximab (sequence 2), and splenectomy-rituximab-romiplostim (sequence 3). A Markov model was built for ITP, and the analysis period was set as 2 years. The discount rate was an annual rate of 2%. Sensitivity analyses of the efficacy of splenectomy, romiplostim, and rituximab; treatment cost; and romiplostim dose were performed. The expected costs per patient over a 2-year period for sequences 1, 2, and 3 were USD 40,980, USD 39,822, and USD 33,551, respectively. The expected years with a platelet count ≥30 × 109/L for the three sequences were 1.75, 1.79, and 1.78 years, respectively. The sensitivity analyses illustrated that the results of the base case analysis were robust. Adding rituximab to standard treatment for ITP (sequences 2–3) is less costly and marginally more effective than standard therapy in adults. According to the study results, if rituximab is reimbursed for the treatment of ITP in Japan, medical expenses are expected to decline.
- 22 January 2015
- Published by Springer Nature in BMC Health Services Research
- Vol. 15 (1) , 2
Open AccessCost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease in which the platelet count falls to <100 × 109/L. Corticosteroids are recommended as the first-line treatment, splenectomy is recommended as the second-line treatment, and thrombopoietin receptor agonists (TPO-RAs) and rituximab are recommended as the third-line treatments for ITP in Japanese ITP treatment guidelines. However, in Japan, rituximab is not eligible for reimbursement for the treatment of ITP. The cost-effectiveness of ITP treatment has not been investigated in Japan. Therefore, in this study, the cost-effectiveness of adding rituximab treatment to the existing treatments indicated for ITP in Japan, namely splenectomy and the TPO-RA romiplostim, was investigated based on the scenario that rituximab is eligible for reimbursement in Japan as a treatment for ITP. The efficacy endpoint was set as the number of years with a platelet count ≥30 × 109/L. The analysis was conducted from the healthcare payer’s perspective. If the first treatment is ineffective or relapse occurs, then the patient is given the following treatment. The analyzed treatment order consisted of three patterns: splenectomy-romiplostim (sequence 1), splenectomy-romiplostim-rituximab (sequence 2), and splenectomy-rituximab-romiplostim (sequence 3). A Markov model was built for ITP, and the analysis period was set as 2 years. The discount rate was an annual rate of 2%. Sensitivity analyses of the efficacy of splenectomy, romiplostim, and rituximab; treatment cost; and romiplostim dose were performed. The expected costs per patient over a 2-year period for sequences 1, 2, and 3 were USD 40,980, USD 39,822, and USD 33,551, respectively. The expected years with a platelet count ≥30 × 109/L for the three sequences were 1.75, 1.79, and 1.78 years, respectively. The sensitivity analyses illustrated that the results of the base case analysis were robust. Adding rituximab to standard treatment for ITP (sequences 2–3) is less costly and marginally more effective than standard therapy in adults. According to the study results, if rituximab is reimbursed for the treatment of ITP in Japan, medical expenses are expected to decline.